Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies
Identifieur interne : 001101 ( Main/Exploration ); précédent : 001100; suivant : 001102Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies
Auteurs : Paul T. Francis [Royaume-Uni] ; Elaine K. Perry [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2007.
English descriptors
- KwdEn :
Abstract
It is now 30 years since the beginning of intensive efforts to understand the neurotransmitter biochemistry of dementia as exemplified by Alzheimer's disease and such studies have led to the development of rational treatment strategies, which are continuing to benefit patients. However, as studies became more sophisticated and clinicians rediscovered an interest in dementia, because of the potential for symptomatic treatment, it has become clear that there are several different neurodegenerative conditions that gives rise to dementia syndromes and that each has distinct neurochemical pathology. This has important treatment implications since what works for one may not work for another or at the extreme, may make matters worse. Therefore it is clear that a detailed understanding of the neurotransmitter function in each condition is not merely academic but can lead to rationale drug design and treatment strategies appropriate for that group of patients. Dementia with Lewy bodies (DLB) has clinico‐pathological features, which overlap with either AD or Parkinson's disease (PD) as well as features that help to distinguish it, such as fluctuations in cognitive impairment and a higher prevalence of visual hallucinations. On this basis, it would be expected that the neurochemistry would have some similarities with both disorders. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21683
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies</title><author><name sortKey="Francis, Paul T" sort="Francis, Paul T" uniqKey="Francis P" first="Paul T." last="Francis">Paul T. Francis</name></author><author><name sortKey="Perry, Elaine K" sort="Perry, Elaine K" uniqKey="Perry E" first="Elaine K." last="Perry">Elaine K. Perry</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BB7BA058CCDB74F4A055F2C1FC14F07093C685D2</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21683</idno><idno type="url">https://api.istex.fr/document/BB7BA058CCDB74F4A055F2C1FC14F07093C685D2/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002D18</idno><idno type="wicri:Area/Main/Curation">002944</idno><idno type="wicri:Area/Main/Exploration">001101</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies</title><author><name sortKey="Francis, Paul T" sort="Francis, Paul T" uniqKey="Francis P" first="Paul T." last="Francis">Paul T. Francis</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>King's College London, Wolfson Centre for Age‐Related Diseases, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Perry, Elaine K" sort="Perry, Elaine K" uniqKey="Perry E" first="Elaine K." last="Perry">Elaine K. Perry</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>King's College London, Wolfson Centre for Age‐Related Diseases, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Institute of Aging and Health Laboratories, University of Newcastle‐Upon‐Tyne, Newcastle‐Upon‐Tyne General Hospital, Newcastle</wicri:regionArea><wicri:noRegion>Newcastle</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007">2007</date><biblScope unit="volume">22</biblScope><biblScope unit="issue">S17</biblScope><biblScope unit="supplement">S17</biblScope><biblScope unit="page" from="S351">S351</biblScope><biblScope unit="page" to="S357">S357</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">BB7BA058CCDB74F4A055F2C1FC14F07093C685D2</idno><idno type="DOI">10.1002/mds.21683</idno><idno type="ArticleID">MDS21683</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>acetylcholine</term><term>behavior</term><term>neurochemistry</term><term>serotonin</term><term>treatment</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">It is now 30 years since the beginning of intensive efforts to understand the neurotransmitter biochemistry of dementia as exemplified by Alzheimer's disease and such studies have led to the development of rational treatment strategies, which are continuing to benefit patients. However, as studies became more sophisticated and clinicians rediscovered an interest in dementia, because of the potential for symptomatic treatment, it has become clear that there are several different neurodegenerative conditions that gives rise to dementia syndromes and that each has distinct neurochemical pathology. This has important treatment implications since what works for one may not work for another or at the extreme, may make matters worse. Therefore it is clear that a detailed understanding of the neurotransmitter function in each condition is not merely academic but can lead to rationale drug design and treatment strategies appropriate for that group of patients. Dementia with Lewy bodies (DLB) has clinico‐pathological features, which overlap with either AD or Parkinson's disease (PD) as well as features that help to distinguish it, such as fluctuations in cognitive impairment and a higher prevalence of visual hallucinations. On this basis, it would be expected that the neurochemistry would have some similarities with both disorders. © 2007 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Francis, Paul T" sort="Francis, Paul T" uniqKey="Francis P" first="Paul T." last="Francis">Paul T. Francis</name></region><name sortKey="Perry, Elaine K" sort="Perry, Elaine K" uniqKey="Perry E" first="Elaine K." last="Perry">Elaine K. Perry</name><name sortKey="Perry, Elaine K" sort="Perry, Elaine K" uniqKey="Perry E" first="Elaine K." last="Perry">Elaine K. Perry</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001101 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001101 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:BB7BA058CCDB74F4A055F2C1FC14F07093C685D2
|texte= Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies
}}
| This area was generated with Dilib version V0.6.23. |  |